These are publications from work undertaken by Frontier Science (Scotland).

P Nuciforo;  C Aura; E Holmes; L Prudkin; J Jimenez; P Martinez; H Ameels; L de la Pena; CE Ellis; H. Eidtmann; M. Piccart; M Scaltriti; J Baselga;  2015

Benefit to Neoadjuvant anti-Human Epidermal Growth Factor Receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) Status

Annals of Oncology,  Volume 26, Issue 7, Pages 1494-1500, doi:10.1093/annonc/mdv175

I J Majewski;  P Nuciforo; L Mittempergher; A J Bosma; H. Eidtmann; E Holmes; C Sotiriou; D Fumagalli; J Jimenez; C Aura; L Prudkin; M C Diaz-Delgado; L de la Pena; S Loi; C Ellis; N Schultz; E. de Azambuja; N Harbeck; M Piccart-Gebhart; R Bernards; J Baselga;  2015

PIK3CA Mutations are Associated with decreased benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2- Targeted Therapies in Breast Cancer

Journal of Clinical Oncology,  Volume 33, Issue 12, Pages 1334-1339, doi:10.1200/JCO.2014.55.2158

G Gebhart;  C Gamez; E Holmes; J Robles; M Cortes; M E de Azambuja; K Fauria; V Van Dooren; G Aktan; M Coccia-Portugal; S Kim; P Vuylsteke; H Cure; H. Eidtmann; J Baselga; M. Piccart; P Flamen; S Di Cosimo;  2013

18F-FDG-PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO

Journal of Nuclear Medicine,  Volume 54, Issue 11, Pages 1862-1868, doi:10.2967/jnumed.112.119271

M Piccart-Gebhart;  E Holmes; J Baselga; E. de Azambuja; AC Dueck; G Viale; J A Zujewski; A Goldhirsch; A Armour; KI Pritchard; A E McCollough; S Dolci; E McFadden; A P Holmes; L Tonghua; H. Eidtmann; P Dinh; S. Di Cosimo; N Harbeck; S Tjulandin; Y H Im; C S Huang; V Dieras;  2016

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-positive Breast Cancer: Results from the Randomized Phase III Adjuvant Lapatinib and/ or Trastuzumab Treatment Optimization Trial

Journal of Clinical Oncology,  Volume 34, Issue 10, Pages 1034-1042, doi:10.1200/JCO.2015.62.1797

E. de Azambuja;  A P Holmes; M Piccart-Gebhart; E Holmes; S. Di Cosimo; R F Swaby; M Untch; C Jackisch; I Lang; I Smith; F Boyle; B Xu; C H Barrios; EA Perez; H A Azim Jr; S Kuemmel; C S Huang; P Vuylsteke; R K Hsieh; V Gorbunova; A Eniu; L Dreosti; N Tavartkiladze;  2014

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomized, open-label, multicentre, phase 3 trial and their association with pathological complete response

The Lancet Oncology,  Volume 15, Issue 10, Pages 1137-1146, doi:10.1016/S1470-2045(14)70320-1

M Scaltriti;  P Nuciforo; I Bradbury; J Sperinde; D Agbor-Tarh; C Campbell; A Chenna; J Winslow; V Serra; JL Parra; L Prudkin; J Jimenez; C Aura;  2015

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab

Clinical Cancer Research,  Volume 21, Issue 3, Pages 569-76, doi:10.1158/1078-0432.CCR-14-1824

CC O’Sulivan;  I Bradbury; C Campbell; M Spielmann; EA Perez; H Joensuu; JP Costantino; S Delaloge; P Rastogi; D Zardavas; KV Ballman; E Holmes; E. de Azambuja; M Piccart-Gebhart; JA Zujewski; RD Gelber;  2015

Efficiacy of Adjuvant Trastuzumab for Patients with Human Epidermal Growth Factor Receptor 2-Positive Early Breat Cancer and Tumors >2cm: A Meta-Analysis of the Randomized Trastuzumab Trials

Journal of Clinical Oncology,  Volume 33, Issue 24, Pages 2600-2608, doi:10.1200/JCO.2015.60.8620

R Salgado;  C Denkert; C Campbell; P Savas; P Nuciforo; C Aura; E. de Azambuja; H. Eidtmann; C Ellis; J Baselga; M Piccart-Gebhart; S Michiels; I Bradbury; C Sotiriou; S Loi;  2015

Tumor-Infiltrating Lymphocytes and Associations with Pathological Complet Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated with Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

JAMA Oncology,  Volume 1, Issue 4, Pages 448-454, doi:10.1001/jamaoncol.2015.0830

A Sonnenblick;  E. de Azambuja; D Agbor-Tarh; I Bradbury; C Campbell; Y Huang; AC Dueck; KI Pritchard; AC Wolff; C Jackisch; I Lang; M Untch; I Smith; F Boyle; B Xu; H Gomez; EA Perez; M. Piccart; H. A. Azim Jr;  2016

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial

Journal of the National Cancer Institute,  Volume 108, Issue 8, doi:10.1093/jnci/djw037

C. Criscitiello;  H. A. Azim Jr; D Agbor-Tarh; E. de Azambuja; M. Piccart; J Baselga; H. Eidtmann; S. Di Cosimo; I Bradbury; IT Rubio;  2013

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2- positive breast cancer: results from the NeoALTTO phase III trial

Annals of Oncology,  Volume 24, Issue No 8, Pages 1980-1985, doi:10.1093/annonc/mdt129